OncoMatch/Clinical Trials/NCT07200102
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Is NCT07200102 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Selinexor for multiple myeloma.
Treatment: Selinexor — The outcomes in patients with relapsed multiple myeloma refractory to triple-therapy (anti-CD38, immunomodulatory drugs (IMiD) and proteasome inhibitors (PI)) remain poor. These patients are eligible for chimeric antigen receptor T-cells (CAR-T), which rely on redirecting autologous T-cells to clear myeloma cells by targeting B-cell maturation antigen (BCMA). BCMA CAR-T therapy is not curative, and unlike autologous stem cell transplant, there is currently no standard for maintenance therapy post CAR-T which could potentially increase MRD rates and extend progression-free survival. Selinexor is an exportin (XPO1) inhibitor with direct anti-tumor effect used often as an adjunct with other agents as bridging therapy prior to CAR-T. As selinexor does not affect T-cell yields or fitness, T-cell collection on selinexor for CAR-T manufacturing is safe. The aim of this study is to evaluate the safety and toxicity of selinexor in triple-exposed or refractory multiple myeloma patients with high-risk features (adverse risk cytogenetics, less than complete response (CR) post CAR-T, or extramedullary disease) following BCMA CAR-T therapy. The investigators hypothesize that selinexor as maintenance therapy following CAR-T has the potential to act synergistically with CAR-T cells leading to more durable responses.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: car-t cell therapy (ciltacabtagene autoleucel) — standard of care
Cannot have received: xpo1 inhibitor (selinexor)
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 50 K/cumm; Hemoglobin ≥ 8.5 g/dL without blood transfusion within 7 days before C1D1
Kidney function
Calculated creatinine clearance ≥ 15 mL/min by Cockcroft-Gault
Liver function
Total bilirubin ≤ 1.5 x IULN; patients with Gilbert's syndrome must have a total bilirubin < 3 x IULN. AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN
Cardiac function
congestive heart failure of NYHA class ≥ 3 or known left ventricular ejection fraction of < 40%, or myocardial infarction within 3 months prior to CAR-T therapy [excluded]
Adequate bone marrow and organ function at Day 30 post CAR-T (+28 /-14 days) as defined below: Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 50 K/cumm; Hemoglobin ≥ 8.5 g/dL without blood transfusion within 7 days before C1D1. Total bilirubin ≤ 1.5 x IULN; patients with Gilbert's syndrome must have a total bilirubin < 3 x IULN. AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN. Calculated creatinine clearance ≥ 15 mL/min by Cockcroft-Gault
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify